A. Richard Szymialis, RPh
Articles by A. Richard Szymialis, RPh
Real-World Outcomes Among Patients With Early Rapidly Progressive Rheumatoid Arthritis
ByAndrew J. Klink, PhD, MPH,Tammy G. Curtice, PharmD, MBA, MS,Kiran Gupta, PhD, MPharm,Kenneth W. Tuell, RPh, BCGP,A. Richard Szymialis, RPh,Damion Nero, PhD,Bruce A. Feinberg, DO This study suggests that lower healthcare resource use and achieving low disease activity are associated with first-line abatacept compared with a first-line tumor necrosis factor-α inhibitor for patients with early rapidly progressive rheumatoid arthritis.